Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tanabe Pharma Corporation
This is a randomized, 2-arm, parallel group, double blind study to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with type 2 diabetes mellitus, who are receiving treatment with insulin therapy on diet and exercise and have inadequate glycemic control. The patients will receive either TA-7284 100mg or Placebo orally for 16 weeks.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational dug
Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug
Patients with HbA1c of ≥7.5% and \<10.5%
Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug
You may not be if
Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)
Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)
Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria
Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg
Patients with serious renal or hepatic disease
Patients with eGFR of \<45 mL/min/1.73 m2
Patients who are the excessive alcohol addicts
Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception